Exploratory Study of MRI Biomarkers of NASH
Recruiting
N/A
Interventional Study
Non-alcoholic Fatty Liver Disease NAFLD
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 110 (estimated)
- Sponsor
- University Hospital, Angers · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Metabolic steatosis disease (NAFLD) is a rapidly growing disease in the world, particularly in industrialized countries.
NAFLD is defined by the presence of fatty liver disease. This is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. Non-invasive quantification, on the other hand, requires MRI.
Nonalcoholic steatohepatitis (NASH) is the aggressive form of…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient included in the SNIFF cohort of the Angers hospital where there is a suspicion of NASH requiring a biopsy for which an MRI is requested by a hepatologist as part of the initial assessment of the disease.
* Adult patient
* Free, informed and express (oral) consent of th…
Contacts